Clinical trialsCompany release

Climb Bio's November deck sets out budoprutug and CLYM116 plans, cash runway into 2H 2028

🇺🇸 Climb Bio, Inc. (CLYM) · Thu 05 Nov 2026

The US antibody developer says its 2026 data guidance was met, with an ITP update due at ASH in December and further data planned for 2027.

Climb Bio has published a corporate presentation dated November 2026 that summarises progress and next steps across its antibody pipeline. The full text of the deck was not available for this report, so the details below rest on the company's own summary of it.

The lead asset, budoprutug, is an anti-CD19 antibody being developed for primary membranous nephropathy, immune thrombocytopenia (ITP) and lupus. The second programme, CLYM116, targets APRIL and is in development for IgA nephropathy.

According to the presentation, Climb Bio met its data guidance for 2026. The company plans an update on ITP at the American Society of Hematology (ASH) meeting in December, and says further data are expected in 2027.

On finances, the deck states that the company's cash is expected to fund operations into the second half of 2028. No further figures were available to us.

What it means for your team

  • Regulatory and clinical teams tracking B-cell-directed and APRIL-targeted therapies can note the December ASH ITP update as the next scheduled disclosure for budoprutug.
  • Further data guided for 2027 may shape the timing of any later regulatory or market-access planning, though the deck summary gives no filing timelines.
  • The stated cash runway into 2H 2028 is a company projection and not a regulatory milestone.

Company's press release (SEC filing): Climb Bio, Inc. ↗

Article written by VigiEye from the official source (Climb Bio, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →